Rüzgar Miroğlu

Haematology 2

Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. Most AML subtypes are distinguished from other related blood disorders by the presence of more than 20% blasts in the bone marrow.The underlying pathophysiology in acute myelogenous leukemia consists of a maturational arrest of bone marrow cells in the earliest stages of development. This developmental arrest results in 2 disease processes. First, the production of normal blood cells markedly decreases, which results in varying degrees of anemia, thrombocytopenia, and neutropenia. Second, the rapid proliferation of these cells, along with a reduction in their ability to apoptosis, results in their accumulation in the bone marrow, blood, and, frequently, the spleen and liver.Acute myelogenous leukemia (AML) is more common in men than in women. The prevalence of AML increases with age. The median age of onset is approximately 70 years.
Patients with AML present with symptoms resulting from bone marrow failure, organ infiltration with leukemic cells, or both.The most common symptom of anemia is fatigue.And they may also  present with fever or history of upper respiratory infection symptoms that have not improved despite empiric treatment with oral antibiotics.Patients present with bleeding gums and multiple ecchymoses. Bleeding may be caused by thrombocytopenia, coagulopathy that results from disseminated intravascular coagulation (DIC).

 

In multiple myeloma renal failure may develop both acutely and chronically. It is commonly due to hypercalcemia.It may also be due to tubular damage from excretion of light chains, also called Bence Jones proteins, which can manifest as the Fanconi syndrome (type II renal tubular acidosis). Other causes include glomerular deposition of amyloid, hyperuricemia, recurrent infections (pyelonephritis), and local infiltration of tumor cells.

 

 

Thrombocytopenia is the presence of relatively low platelets in blood.In human beings a normal platelet count ranges from 150,000 to 450,000 platelets per 1ml of blood.Often, low platelet levels do not lead to clinical problems rather, they are picked up on a routine full blood count. Occasionally, there may be bruising, particularly purpura in the forearms,petechia (pinpoint hemmorages on skin and mucous membranes) nosebleeds and/or bleeding gums.If the person’s platelet count is between 30,000 and 50,000/mm3, bruising with minor trauma may be expected; if it is between 15,000 and 30,000/mm3, spontaneous bruising will be seen.
Decreased platelet counts can be due to a number of disease processes.
 
Decreased production
* Vitamin B12 or folic acid deficiency
* Leukemia or myelodysplastic syndrome
* Decreased production of thrombopoietin by the liver in liver failure.
* Sepsis, systemic viral or bacterial infection
* Dengue fever can cause thrombocytopenia by direct infection of bone marrow megakaryocytes as well as immunological shortened platelet survival
* Hereditary syndromes
Fanconi anemia
Bernard-Soulier syndrome, associated with large platelet
Alport syndrome
 
Increased destruction
* Idiopathic thrombocytopenic purpura (ITP)
* Paroxysmal nocturnal hemoglobinuria (PNH)
* Neonatal alloimmune thrombocytopenia
* Hypersplenism
* HIV-associated thrombocytopenia

 

 

Thrombotic Thrombocytopenic Purpura is a rare disorder of the blood-coagulation system, causing extensive microscopic thromboses to form in small blood vessels throughout the body.Most cases of TTP arise from inhibition of the enzyme ADAMTS13, a metalloprotease responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. Microthrombi formation in the blood vessels lead to Intravascular hemolysis,schistocyte formation and Reduced blood flow due to thrombosis and cellular injury results in end organ damage.
Classically, the following five features are indicative of TTP
* Fluctuating Neurologic symptoms such as hallucinations, bizarre behavior, altered mental status, stroke or headaches
* Kidney failure
* Fever
* Thrombocytopenia leading to bruising or purpura
* Microangiopathic hemolytic anemia
Due to the high mortality of untreated TTP, a presumptive diagnosis of TTP is made even when only microangiopathic hemolytic anemia and thrombocytopenia is seen, and therapy is started.Current therapy is based on support and plasmapheresis to reduce circulating antibodies against ADAMTS13 and replenish blood levels of the enzyme.

 

 

Disseminated intravascular coagulation (DIC) is a pathological activation of coagulation mechanisms that happens in response to a variety of diseases. DIC leads to the formation of microthrombi inside the blood vessels throughout the body.As the microthrombi consume coagulation proteins and platelets, normal coagulation is disrupted and abnormal bleeding occurs from the skin , the gastrointestinal tract, the respiratory tract and surgical wounds.
In DIC, the processes of coagulation and fibrinolysis are dysregulated, and the result is widespread clotting with resultant bleeding. One critical mediator of DIC is the release of tissue factor. TF binds with coagulation factors that then triggers the extrinsic pathway which subsequently triggers the intrinsic pathway of coagulation.Excess circulating thrombin results from the excess activation of the coagulation cascade. The excess thrombin cleaves fibrinogen, which ultimately leaves behind multiple fibrin clots in the circulation. These excess clots trap platelets to become larger clots, which leads to microvascular and macrovascular thrombosis. This lodging of clots in the microcirculation, in the large vessels, and in the organs is what leads to the ischemia, impaired organ perfusion, and end-organ damage that occurs with DIC.Simultaneously, excess circulating thrombin assists in the conversion of plasminogen to plasmin, resulting in fibrinolysis. The breakdown of clots results in excess amounts of FDPs, which have powerful anticoagulant properties, contributing to hemorrhage.
Definitive diagnosis of DIC depends on the result ofThrombocytopenia,Prolongation of prothrombin time and activated partial thromboplastin time,A low fibrinogen concentration and Increased levels of fibrin degradation products.

 

 

Thalassaemia is a inherited autosomal recessive hemoglobinopathy. There are different types of thalassaemia.Haemoglobin is made out of two ‘alpha chains’ and two ‘beta chains’ which are put together to make the haemoglobin molecule.In thalassaemia, defect of either the alpha chains or the beta chains.The main types of thalassaemia are called alpha thalassaemia and beta thalassaemia.Each type of thalassaemia has several sub types.The mildest types are called thalassaemia trait. The more severe beta types are beta thalassaemia major and beta thalassaemia intermedia.The more severe alpha forms are Hb Barts and Hb H disease.
Hb H disease is due to having three missing alpha haemoglobin genes.It usually causes a mild but persistent anaemia. Sometimes Hb H causes more symptoms and is similar to beta thalassaemia intermedia (explained below). Some people with Hb H disease need blood transfusions.
Hb Barts is the most severe form of alpha thalassaemia, where all the alpha haemoglobin genes are abnormal or missing. It occurs if a baby inherits two alpha zero thalassaemia genes. In this condition, no normal haemoglobin can be made, even before birth. It is the most serious form of thalassaemia – so serious that the baby will usually die in the uterus from severe anaemia.
Beta thalassemia major or Cooley’s anemia results if both alleles have thalassemia mutations. This is a severe microcytic, hypochromic anemia. If Untreated, it causes anemia, splenomegaly, and severe bone deformities. It progresses to death before age twenty. Treatment consists of periodic blood transfusion; splenectomy if splenomegaly is present, and treatment of transfusion-caused iron overload. Cure is possible by bone marrow transplantation.
In Beta thalassemia minor only one beta globin allele bears a mutation. This is a mild microcytic anemia. Detection usually involves measuring the mean corpuscular volume and increased fraction of Hemoglobin A2 and a decreased fraction of Hemoglobin A.

 

Myelodysplastic syndromes (MDS) are a collection of hematological conditions united by ineffective production of myeloid blood cells and risk of transformation to acute myeloid leukemia (AML). Myelodysplastic syndromes has been found in humans, cats and dogs. Anemia requiring chronic blood transfusion is frequently present.
Myelodysplastic syndromes are bone marrow stem cell disorders resulting in disorderly and ineffective hematopoiesis (blood production) manifested by irreversible quantitative and qualitative defects in hematopoietic (blood-forming) cells. In a majority of cases, the course of disease is chronic with gradually worsening cytopenias due to progressive bone marrow failure. Approximately one-third of patients with MDS progress to AML within months to a few years.There is no cure for myelodysplastic syndromes. Treatment for myelodysplastic syndromes usually focuses on reducing or preventing complications of the disease and of treatments. In certain cases, myelodysplastic syndromes are treated with a bone marrow transplant, which may help prolong life.

 

HEMOLYTIC UREMIC SYNDROME(HUS) is part of microangiopathic hemolytic anemia that encompass Thrombotic thrombocytopenic purpura (TTP) and HUS. The classic childhood case of HUS occurs after bloody diarrhea caused by a strain of E. coli that expresses Shiga-like toxin or EHEC (Enterohemorrhagic E. coli). HUS follows an influenza-like or gastrointestinal (GI) prodrome with bleeding manifestations, severe oliguria, hematuria, a microangiopathic hemolytic anemia, and occatinally prominent neurologic changes.The typical pathophysiology involves the shiga-toxin binding to proteins on the surface of glomerular endothelium and inactivating a metalloproteinase ADAMTS13.Once the ADAMTS13 is disabled multimers of vWF form and initiate platelet activation and cause microthrombi formation. In contrast with typical DIC , coagulation factors are not consumed in HUS and the coagulation screen, fibrinogen level, and assays for fibrin degradation products such as “D-Dimers”, are generally normal despite the thrombocytopenia.

 

Blood transfusion is the process of transferring blood or blood products from one person into the circulatory system of another. It can be life-saving in some situations, such as massive hemorrhages due to trauma, or can be used to replace blood loss in surgery. Blood transfusions may also be used to treat a severe anaemia or thrombocytopenia caused by hematological diseases. People suffering from Thalassemia,hemophilia or sickle-cell disease may require frequent blood transfusions.Early transfusions used whole blood, but modern medical practice commonly uses only components of the blood.
Donated blood is usually subjected to processing after it is collected, to make it suitable for use in specific patient populations.These are include:
Component separation
Leukoreduction(Leukodepletion) is the removal of WBC from the blood product by filtration. Leukoreduced blood is less likely to cause alloimmunization (development of antibodies against specific blood types),and less likely to cause febrile transfusion reactions.

 

The myeloproliferative diseases(MPD) are a group of diseases of the bone marrow in which excess cells are produced. They are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia.There are four main myeloproliferative diseases, which can be further categorized by the presence of the Philadelphia chromosome:
Philadelphia Chromosome “positive” -Chronic myelogenous leukemia (CML)
Philadelphia Chromosome “negative” – Polycythemia vera (PV),Essential thrombocytosis(ET),Myelofibrosis (MF)
All MPDs arise from precursors of the myeloid lineage in the bone marrow.Depending on the type of the MPD, diagnostic tests may include red cell mass determination,bone marrow aspirate and trephine biopsy,oxygen saturation and carboxyhaemoglobin level,neutrophil alkaline phosphatase level, vitamin B12 and serum urate.
 

Bu web sitesi ücretsiz olarak Bedava-Sitem.com ile oluşturulmuştur. Siz de kendi web sitenizi kurmak ister misiniz?
Ücretsiz kaydol